StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Analysts at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

A number of other research firms also recently issued reports on VNRX. D. Boral Capital reiterated a “buy” rating and set a $5.00 target price on shares of VolitionRx in a research report on Thursday, February 6th. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.63 on Friday. The firm’s fifty day moving average is $0.62 and its 200-day moving average is $0.65. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.11. The firm has a market cap of $58.10 million, a P/E ratio of -1.74 and a beta of 1.20.

Insider Buying and Selling

In other VolitionRx news, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was bought at an average cost of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, with a total value of $99,615.48. Following the completion of the acquisition, the director now owns 617,085 shares in the company, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 358,266 shares of company stock worth $204,212. Insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after buying an additional 95,900 shares in the last quarter. Ground Swell Capital LLC raised its position in VolitionRx by 78.8% in the 3rd quarter. Ground Swell Capital LLC now owns 45,959 shares of the company’s stock worth $28,000 after purchasing an additional 20,249 shares during the period. Northern Trust Corp raised its position in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the period. Finally, Two Sigma Securities LLC bought a new stake in VolitionRx in the 4th quarter worth $29,000. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.